Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool

Abstract Background iPrevent is an online breast cancer (BC) risk management decision support tool. It uses an internal switching algorithm, based on a woman’s risk factor data, to estimate her absolute BC risk using either the International Breast Cancer Intervention Study (IBIS) version 7.02, or Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm version 3 models, and then provides tailored risk management information. This study assessed the accuracy of the 10-year risk estimates using prospective data. Methods iPrevent-assigned 10-year invasive BC risk was calculated for 15 732 women aged 20–70 years and without BC at recruitment to the Prospective Family Study Cohort. Calibration, the ratio of the expected (E) number of BCs to the observed (O) number and discriminatory accuracy were assessed. Results During the 10 years of follow-up, 619 women (3.9%) developed BC compared with 702 expected (E/O = 1.13; 95% confidence interval [CI] =1.05 to 1.23). For women younger than 50 years, 50 years and older, and BRCA1/2-mutation carriers and noncarriers, E/O was 1.04 (95% CI = 0.93 to 1.16), 1.24 (95% CI = 1.11 to 1.39), 1.13 (95% CI = 0.96 to 1.34), and 1.13 (95% CI = 1.04 to 1.24), respectively. The C-statistic was 0.70 (95% CI = 0.68 to 0.73) overall and 0.74 (95% CI = 0.71 to 0.77), 0.63 (95% CI = 0.59 to 0.66), 0.59 (95% CI = 0.53 to 0.64), and 0.65 (95% CI = 0.63 to 0.68), respectively, for the subgroups above. Applying the newer IBIS version 8.0b in the iPrevent switching algorithm improved calibration overall (E/O = 1.06, 95% CI = 0.98 to 1.15) and in all subgroups, without changing discriminatory accuracy. Conclusions For 10-year BC risk, iPrevent had good discriminatory accuracy overall and was well calibrated for women aged younger than 50 years. Calibration may be improved in the future by incorporating IBIS version 8.0b.

[1]  M. Kumle Declining breast cancer incidence and decreased HRT use , 2008, The Lancet.

[2]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[3]  Danielle Braun,et al.  Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications , 2017, Breast Cancer Research and Treatment.

[4]  McGinnis Jm,et al.  The learning healthcare system : workshop summary , 2007 .

[5]  Jacques Simard,et al.  Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model , 2016, Genetics in Medicine.

[6]  A. LaCroix,et al.  Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data , 2013, The Lancet.

[7]  S. Astley,et al.  Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction , 2018, JAMA oncology.

[8]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[9]  J. Emery,et al.  Consumer and clinician perspectives on personalising breast cancer prevention information. , 2019, Breast.

[10]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[11]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[12]  Linn Brandt,et al.  A systematic review of trials evaluating success factors of interventions with computerised clinical decision support , 2018, Implementation Science.

[13]  Gord Glendon,et al.  10-year performance of four models of breast cancer risk: a validation study. , 2019, The Lancet. Oncology.

[14]  Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC) , 2018, Breast Cancer Research.

[15]  J. Emery,et al.  Assessing and managing breast cancer risk: clinicians' current practice and future needs. , 2014, Breast.

[16]  J. Hopper,et al.  Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort , 2004, Familial Cancer.

[17]  D. Kennedy,et al.  Double-strand breaks repair in lymphoblastoid cell lines from sisters discordant for breast cancer from the New York site of the BCFR. , 2008, Carcinogenesis.

[18]  Jack Cuzick,et al.  Long-term Accuracy of Breast Cancer Risk Assessment Combining Classic Risk Factors and Breast Density , 2018, JAMA oncology.

[19]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[20]  M. García-Closas,et al.  BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors , 2019, Genetics in Medicine.

[21]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[22]  K. Friese,et al.  [Early detection of breast cancer]. , 2008, MMW Fortschritte der Medizin.

[23]  Karla Kerlikowske,et al.  Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.

[24]  Yvonne Vergouwe,et al.  A calibration hierarchy for risk models was defined: from utopia to empirical data. , 2016, Journal of clinical epidemiology.

[25]  J. Emery,et al.  iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management , 2016, Breast Cancer Research and Treatment.

[26]  J. Emery,et al.  Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease? , 2016, Australian journal of primary health.

[27]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[28]  W. Willett,et al.  Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: A nested case–control study , 2018, PLoS medicine.

[29]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[30]  H A Risch,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[31]  B. Bonanni,et al.  A Survey among Breast Cancer Specialists on the Low Uptake of Therapeutic Prevention with Tamoxifen or Raloxifene , 2017, Cancer Prevention Research.

[32]  A. Whittemore,et al.  Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC) , 2015, International journal of epidemiology.

[33]  J. Emery,et al.  The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing , 2018, JMIR formative research.

[34]  W. Chung,et al.  Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial Risk , 2018, Journal of the National Cancer Institute.